COMP <GO>
PBYI vs EVO // EV/EBITDA & P/E VALUATION
Puma Biotechnology Inc (NASDAQ) VS. Evotec SE (NASDAQ) • 15-METRIC TALLY: PBYI 1
— EVO 1
■ METRIC PARITY
LAST: $10.54 (-0.75%) • MKT CAP: $544.1M
valuation
13.8x
LAST: $1.58 (-1.56%) • MKT CAP: $562.1M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PBYI VS. EVO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PBYI | EVO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 74.50% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 29.30% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 13.8x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 7.67% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | 16.30% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | 13.60% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | -0.90% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 52.9 | 47.2 | +5.70 | PBYI | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 16.3x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $544.1M | $562.1M | -$18.0M | EVO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PBYI REV | EVO REV | PBYI GROSS % | EVO GROSS % | PBYI FCF | EVO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $228.4M | — | 74.5% | — | $41.7M | — |
| FY 2024 | $230.5M | — | 72.1% | — | $38.9M | — |
| FY 2023 | $235.6M | — | — | — | $27.0M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PBYI // BETA —
EVO // BETA —